Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S1007: Adjuvant Endocrine Therapy With or Without Chemotherapy in Node-Positive HR+/HER2- Breast Cancer (RS ≤ 25)
2012-000576-42Phase 3Active
- Sponsor
- Cancer Trials Ireland
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tamoxifen in breast cancer (2 arms), sponsored by Cancer Trials Ireland. Primary endpoint: Effect of chemotherapy on node-positive HR+/HER2- breast cancer with RS ≤ 25. Started Feb 2012; status: active.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-000576-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000576-42.